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Critical Assessment of Epidemiologic
Studies on the Human Carcinogenicity of
1,3-Butadiene
by Philip J. Landrigan*
1,3-Butadiene, a major ingredient ofsynthetic rubber, has been shown to be carcinogenic in two animal
species. To assess the possible human carcinogenicity of1,3-butadiene, acritical review was undertaken of
the epidemiologic literature.
An early retrospective study of 8017 males employed in tire manufacturing found excess mortality for
lymphatic andhematopoietic neoplasms in production workers (standardized mortalityratio, SMR = 560);
theseworkerswereexposedto1,3-butadiene aswellastostyreneandpossiblytobenzene.Arecentlyupdated
epidemiologic study of2568 workers at a butadiene manufacturing plant in Texas reported low mortality
overall (SMR = 84) butfound excessdeaths forlymphosarcoma andreticulum cell sarcoma(SMR = 229). A
retrospective study ofworkers employed at two synthetic rubberplants in Texas found excess mortality for
lymphatic and hematopoietic malignancies in the olderofthese facilities; the excesses forlymphosarcoma
(SMR = 224)andleukemia(SMR = 278)weremostsignificantinwartimeworkers.Alarge, recentlyupdated
retrospectivestudyof12,113workersemployedineightsyntheticrubbermanufacturingplantsintheUnited
States and Canada found excess mortality forlymphatic and hematopoietic cancer in production workers;
the SMR for other lymphatic cancers in white production workers was 230, and the SMR for all lymphatic
malignancies in black production workers was 507.
These updated epidemiologic results strongly suggest an etiologic association between occupational
exposureto1,3-butadiene andhumancancer. Itisreasonable, therefore, toconcludethattherenowexistsat
least limited evidence for the human carcinogenicity of 1,3-butadiene.
Introduction
1,3-Butadiene is a major component ofsynthetic rub-
ber manufacture. Annual production in the United
Statesis a2.7billionpounds (1). 1,3-Butadiene is among
the top 20 organic chemicals in annual volume.
1,3-Butadiene has been found to produce cancer at
multiple anatomic sites in two species of experimental
animals-rats and mice (2,3). In both species, cancer
occurs at exposure levels equal to or below the current
federal standard of 1000 parts per million (ppm). In
B6C3F1 mice increased incidences were noted ofmalig-
nant lymphoma and cardiachemangiosarcoma; excesses
were seen also of alveolar-bronchiolar neoplasms, tu-
mors of the forestomach, carcinomas of the mammary
gland, neoplasms ofthe ovary, and hepatocellular neo-
plasms (2). In Sprague-Dawley rats, increases were
seen in pancreatic adenoma, uterine sarcoma, Zymbal
glandcarcinoma, mammarytumors, thyroid tumorsand
testicularcancers(3). Nonneoplastictoxiceffectsinmice
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included anemia (at exposure level of 62.5 ppm), tes-
ticular atrophy (at 200 and 625 ppm), and ovarian at-
rophy (at 20 ppm) (4). 1,3-Butadiene has been found to
exhibit genetic toxicity and cytotoxicity in mouse bone
marrow; cytogenetic changes included increased fre-
quencies of chromosomal aberrations (at 625 ppm), of
micronucleus formation (at 625ppm), and ofsisterchro-
matid exchange at (6.25 ppm) (5).
Four epidemiologic studies have been undertaken to
evaluate the possible human health effects of occu-
pational exposure of1,3-butadiene. Three ofthese anal-
yses were updated substantially in preparation for the
1988 International Symposium on the Toxicology, Car-
cinogenesis, and Human Health Aspects of 1,3-Bu-
tadiene held atthe National Institute ofEnvironmental
Health Sciences (NIEHS), Research Triangle Park,
NC. This review will examine critically the current
epidemiologic evidence on the human carcinogenicity of
1,3-butadiene.
North Carolina Study
Anearlyretrospectiveepidemiologic studyconducted
by the Occupational Health Studies Group at the Uni-
versity of North Carolina examined the cause-specificP. J. LANDRIGAN
mortality of 8017 male workers employed at two tire
manufacturing plants in Ohio (6,7).
Overall excess mortality was observed for cancer of
the stomach and for malignancies of the hematopoietic
and lymphatic system. The data were examined sepa-
rately for workers in different job categories. In the
syntheticplant-aworkareawhichinvolved production
of elastomers, including styrene-butadiene rubber
(SBR)-relative risks of 5.6 for lymphatic and hema-
topoietic malignancies and of3.7 forlymphatic leukemia
were reported among workers employed for more than
five years; workers in that area may also have had
exposures to organic solvents, including benzene. The
North Carolina study was not updated for this NIEHS
symposium.
Texaco Study
Thisretrospective studyofthemortality ofacohortof
2586 workers employed for at least 6 months between
1943 and 1979 at a 1,3-butadiene manufacturing facility
in Texas was analyzed previously for mortality through
1979 (8). Quantitative data on past exposures were not
available. However, a qualitative exposure scale was
constructed, based on department codes. Four groups
were defined: low exposure (Group I); routine exposure
(Group II), which included process workers; nonroutine
exposure (Group III), which included maintenance
workers; and unknown exposures (Group IV).
The previous analysis found lower-than-expected
mortality for most causes ofdeath with an overall stan-
dardizedmortalityratio(SMR)incomparisontonational
rates of80. However, astatistically significant excess of
deaths was observed for lymphosarcoma and reticulum
cell sarcoma (SMR 235; 95% CI = 101 to 463).
Mortality was examined relative to the duration of
employment. For all lymphatic and hematopoietic neo-
plasms, the SMR was higherinworkers withlessthan 5
years ofemployment (SMR = 167) than for those with
more than 5 years (SMR = 127). No comment is pro-
vided as towhether the short-term workers might have
been wartime workers (inwartime, exposure waslikely
tohavebeenheavierthaninsubsequentperiods); alsono
informationisprovided onthetypesofworkinwhichthe
short-term employees were engaged.
Mortality ofthis cohort was analyzed for each of the
four exposure groups. Elevated mortality for all lym-
phatic and hematopoietic neoplasms (SMR = 187) was
seen in Group II (routine exposure); this excess was
explained principally by excess mortality for Hodgkin's
disease (SMR = 197) andforotherlymphomas (SMR =
282). In Group III (nonroutine exposure), mortality for
allhematopoieticneoplasms wasagainelevated(SMR =
167), with excess mortality for Hodgkin's disease (SMR
= 130), leukemia(SMR = 201) and non-Hodgkin's lym-
phoma (SMR = 150).
Finally, mortality in this cohort was compared be-
tween blacks and whites. Blacks composed 6.8% ofthe
cohort (175 of 2586 persons). SMRs for blacks were
higherthanthose forwhites forseveral causes ofdeath,
includingarteriosclerotic heartdisease and cancerofthe
lymphatic and hematopoietic system.
At the NIEHS symposium, the mortality experience
ofthe Texaco cohort was updated through 1985 (9). The
authors found the SMR for all causes to be 84 and the
SMR for all cancers to be 80. One additional death from
lymphosarcoma had occurred since the previous analy-
sis, giving a statistically significant excess mortality
ratio of 229, a finding consistent with the previously
noted excess mortality for lymphosarcoma. On updated
analysis by exposure group, the strongest excesses for
lymphatic and hematopoietic malignancy were again
seen in Groups II (process workers) and III (mainte-
nance workers); in process workers, the SMR for lym-
phosarcoma was 561. As seen previously, excess mor-
tality was concentrated in workers employed for less
thanten years and inworkers employed duringthe war;
in wartime workers the SMR for lymphosarcoma was
269.
In interpreting the Texaco studies, the most striking
finding is the consistently elevated mortality for lym-
phosarcoma. This finding is consistent with the animal
data (2,4). It is noteworthy that excess risk was con-
centrated in production and maintenance workers (ex-
posureGroups II and III);bothofthoseobservationsare
consistent with the notion that the incidence of lym-
phatic malignancy is highest in groups with heaviest
occupational exposure to 1,3-butadiene. The authors
notethatmostcasesofmalignancywereconcentrated in
workers employed forless than 10 years. That comment
must be understood in the context that most of those
brief exposures appear to have occurred during the
wartime years when exposures were undoubtedly
higherthaninsubsequentperiods. Thus, thefindingofa
high incidence of malignancy in short-term employees
cannot be used to discount the notion ofdose-response;
instead that finding must be interpreted with the real-
ization that duration of employment is only a crude
surrogate for total cumulative exposure (10).
NIOSH Study
Following the occurrence in January 1976 of two
deaths from leukemia in workers employed at adjacent
styrene-butadiene (SBR) production facilities in Port
Neches, TX, the National Institute for Occupational
Safety and Health (NIOSH) undertook, a retrospective
mortality study of the total population of 2,756 white
males employed in these plants (11). Cohort members
were all workers employed in these plants for at least 6
monthsbetween 1943and 1976. Theplantsused as araw
material the 1,3-butadiene produced by the adjacent
Texaco facility, the subject ofthe previous study (8,9).
Overall mortality (SMR = 80) and mortality from all
malignancies (SMR = 78) weredepressedintheolderof
theseplants(PlantA). Thetotalnumberofdeathsinthis
plant was 252, with 45 deaths from malignant neo-
plasms. Elevated, although not statistically significant,
mortalitywasobservedforlymphaticandhematopoietic
neoplasms (SMR = 155). This excess was explained
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principally by excesses for lymphosarcoma and re-
ticulum cell sarcoma (SMR = 181) and for leukemia
(SMR = 203).
Mortality was examined separately forthe subgoup of
the Plant A population employed during the wartime
years (January 1943 through December 1945). In these
wartimeworkers, an excess was seen formortalityfrom
lymphatic and hematopoietic malignancies (SMR =
212); statistically significant increases in mortality were
seen for lymphosarcoma and reticulum cell sarcoma
(SMR = 224) and for leukemia (SMR = 278).
AtPlantBwheredatawereavailableonlyforworkers
employed from 1950 to 1976 and where only 201 deaths
hadoccurred, overallmortality waslow(SMR = 66). No
excess mortality was seen either for all cancers com-
bined (SMR = 53) or for lymphatic and hematopoietic
neoplasms (SMR = 78).
The NIOSH study was updated for the NIEHS sym-
posium (12). Mortality of the cohort was followed
through 1981 for Plant B and through 1982 for Plant A.
Overall mortality remained low. Mortality in Plant A
from all lymphatic and hematopoietic neoplasms was
found in this reanalysis to again be elevated. As in the
previousanalysis, themajorincreasein cancermortality
was found to have occurred in the wartime subcohort in
Plant A.
No excess mortality was seen in Plant B in the up-
dated analysis.
Considerable similarities exist between the overali
findings ofthe NIOSH and the Texaco studies, and 116
(4.5%) of the workers in the Texaco cohort were also
members of the NIOSH cohort. Both studies found
excess mortality for malignancies of the lymphatic and
hematopoietic system. These findings are consistent
with the animal studies (2,4). Both studies found also
that excess mortality from lymphatic malignancies was
concentrated in workers employed during the wartime
years, which were presumably a period of particularly
intense exposure to 1,3-butadiene.
Matanoski Study
Thelargestepidemiologicstudyofworkersexposedto
1,3-butadiene is that reported by Matanoski et al. (13).
Intheirinitial analysis completed in 1982, mortality was
analyzed for 13,920 workers employed for more than 1
year in eight-styrene-1,3-butadiene rubber production
plants in the United States and Canada. Inthat analysis
10,899 (78.3%) members ofthe cohort were known to be
alive, 2,097 (15.5%) were known to be deceased, and
vital status was not known for 924 (6.6%). A total of
1,041 (7.5%) members of the cohort were black; 12,567
(90.2%) were white.
Overall mortality was low in the initial analysis (SMR
= 81). Mortality for all cancers was also low (SMR =
84). For all lymphatic and hematopoietic cancers, the
SMR was 85 (Table 1). A racial difference was noted,
however, for lymphatic and hematopoietic cancers; an
SMR of 141 was noted in blacks as compared to 80 in
whites. Overall, in the initial analysis, no statistically
significant excesses in mortality from cancer at any site
werenotedineitherthewhite ortheblackpopulations in
this large cohort.
No quantitative information on past exposures was
available in that initial analysis by Matanoski et al. (14).
However in an effort to assess variations in mortality in
relation to qualitative variations in exposure, job cat-
egories in this cohort were classified into four groups:
production, maintenance, utilities, and other. In the
utilities workers, an SMR of198 was noted forleukemia
(based on two deaths). Slight excesses were seen for
Hodgkin's disease in all fourcategories (SMRs from 129
to 345, based on a total of 8 deaths).
Matanoski reanalyzed the mortality of this cohort in
preparation for the NIEHS symposium (14) and re-
structured the cohort. The most significant change was
the removal ofCanadian workers who had not qualified
forpension benefits. This change reduced the size ofthe
population to 12,113. Follow-up was completed through
1982. A total of 2,441 deaths were identified. The pro-
portion ofthe cohortlostto follow-up wasreduced to 416
(3.4%), a substantial improvement over the previous
effort.
Overall analysis of mortality indicated an SMR for
whites of 79 and for blacks of 95. Mortality from all
malignant neoplasms was 78.
For lymphatic and hematopoietic malignancies, no
overall increases were observed in whites (SMR = 92).
In blacks, based on small numbers, overall increased
mortality was seen for lymphopoietic malignancies
(SMR = 146), and specific increases were noted for
lymphosarcoma (SMR = 132), leukemia (SMR = 218),
and other lymphatic neoplasms (SMR = 116).
When the cohort was subdivided by exposure groups,
excess mortality for lymphatic and hematopoietic neo-
Table 1. Mortality from hematopoietic malignancies in published studies on workers occupationally exposed to 1,3-butadiene
in the United States.a
Matanoski et al. (14) Divine (9)
White production Black production Process workers
Type of malignancy All whites All blacks workers workers Total cohort (Group II)
All hematologic 92 146 110 507 130 177
Lymphosarcoma 56 132 0 532 229 561
Hodgkin's disease 131 0 131 0 141 179
Leukemia 86 218 84 656 102 56
Other lymphatic 110 116 230 482 97 80
aMortality is expressed as standardized mortality ratio (SMR).
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plasms was observed in production workers of both
races. In white production workers, the SMR for all
lymphatic and hematopoietic malignancies was 110; that
excess wasexplainedprincipally byexcessmortalityfor
other lymphatic neoplasms (SMR = 230). For black
production workers, based on small numbers, the SMR
for all lymphatic and hematopoietic neoplasms was 507.
That overall increase reflected an SMR of532 for lym-
phosarcoma, of 656 for leukemia and of 482 for other
lymphatic malignancies. A pattern of excess mortality
for lymphatic and hematopoietic neoplasms was seen
alsointhesmallgroupofutilityworkers;includedinthat
group were workers in the tank farm. No increases in
lymphatic or hematopoietic malignancy were seen in
maintenance or other workers.
On the basis of these findings, Matanoski et al. (14)
concluded intheirupdated analysis thatthereis "excess
risk of death from hematologic neoplasms especially
leukemia and other lymphomas in production workers"
occupationally exposed to 1,3-butadiene (14). They sug-
gest that this finding warrants further examination of
the exposures associated with work in this industry.
In interpreting the results ofthe Matanoski studies,
the most significant methodologic differences between
the first and second analyses are a) the extension ofthe
follow-up, b) the improved tracing ofthe cohort, and c)
the deletion ofCanadian workers with relatively short-
term exposure. With those changes, an excess in mor-
tality from lymphatic and hematopoietic malignancy,
which had not been evident initially, became visible.
Information on mortality in specific plants was not
provided.
Discussion
The epidemiologic data on 1,3-butadiene presented at
the NIEHS symposium are most exciting, and they
embody major advances in the understanding of the
health effects ofthis important compound. On the basis
ofthesenewdata, asignificantly enhancedassessmentis
possible on the risk of 1,3-butadiene to man.
Critical review of the new epidemiologic data indi-
cates that a picture, which was only faintly visible 5
years ago, is now comingmore sharplyinto focus. All of
the newer studies have consistently shown excess mor-
tality for lymphatic and hematopoietic cancer. Lym-
phatic neoplasms were noted also in mice exposed to
1,3-butadiene (2).
Qualitative evidence that carcinogenicity in persons
exposed to 1,3-butadiene is dose-related is provided by
the observation that excess mortality is greatest in
productionworkersandmaintenanceworkers, butisnot
seeninoffice staff(8,9,14). Typically, inindustrialpopu-
lations production workers and maintenance workers
are the groups mostheavily exposed topotentiallytoxic
substances. Further evidence for a positive dose-re-
sponse relationship is provided by the observation that
the greatest excess mortality is seen among workers
exposed to 1,3-butadiene during the war years; pre-
sumably that was a period when exposures were espe-
ciallyintense, bothbecause ofwartime production pres-
sures and possible upsets during process start-up
periods.
Criticism has been leveled against the apparent con-
sistency of these epidemiologic findings on the ground
that different subtypes oflymphatic and hematopoietic
neoplasmswere seeninthedifferentstudies (8,9,15,16).
However, it is important to realize that the diagnostic
categories in this area are imprecise and overlapping
(17). Transitions oflymphomas and multiple myelomas
into leukemias are seen frequently in clinical practice,
and a leukemic phase is seen commonly in cases of
non-Hodgkin's lymphoma. In addition, some patients
with lymphoma or multiple myeloma may subsequently
develop leukemia as a result of their treatments with
radiation or cytotoxic drugs (18). These natural and
iatrogenic transitions from lymphoma to leukemia are
complicated further by historical changes in no-
menclature. Indeed, certainlymphomasand certainleu-
kemias such as chronic lymphatic leukemia are now
considered by Berard et al. (19) "simply to represent
different clinicalexpressions ofthe same neoplasticpro-
cess." Further, recentimmunologic (20)andcytogenetic
(21) studies have shown that there are stem cells which
appear to have the capacity to develop variously into
T-cell lymphocytes, plasma cells, granulocytic cells,
erythrocytes or monocytes. Accordingly, transforma-
tion events that occur in these cells at an early multi-
potentlevelcanbemanifestasmalignancyinvolvingany
ofthedaughtercelllines. Forallofthesereasons, undue
insistence on the argument that different lymphatic
malignancies represent etiologically distinct entities ap-
pears to be misplaced.
Conclusion
On the basis of the updated epidemiologic evidence
presented at the NIEHS symposium, it is reasonable to
conclude that there now exists at least limited evidence
for the carcinogenicity of 1,3-butadiene to man. Pre-
viously, the human evidence was considered to be in-
sufficient to permit a determination ofpossible carcino-
genicity (22). This updated conclusion, taken together
with the previous determination by the International
Agency for Research on Cancer (IARC) that there ex-
ists sufficient evidence forthe carcinogenicity of1,3-bu-
tadiene to animals, signifies that it will be prudent
henceforth to treat 1,3-butadiene as though it were a
human carcinogen (23). Indeed, in 1984, the National
Institute for Occupational Safety and Health (NIOSH)
recommended that 1,3-butadiene be regarded as a po-
tential occupational carcinogen (23).
The major shortcoming in the current understanding
ofthe carcinogenicity of1,3-butadiene is a lack ofquan-
titative data on exposure. None of the epidemiologic
studies currently available has developed sufficient in-
formation on exposure to permit description of a quan-
titative dose-response relationship orto serve as abasis
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forquantitative estimationofrisk. Forthefuture, quan-
titative epidemiologicstudieswillthereforeberequired.
These studies will need to link mortality outcomes with
data on cumulative exposures to 1,3-butadiene. Prob-
ably the most efficient approach to achieving this goal
will be to create job-exposure matrices in already-
established cohorts and then to undertake nested case-
control studies (24). Also, additional toxicologic studies
will be required to better delineate the mechanisms of
carcinogenicity of 1,3-butadiene (2,16).
Finally, it is most important from the perspective of
public health and preventive medicine to urge that re-
duction of the occupational exposure standard for
1,3-butadiene not be delayed while additional research
continues. The available toxicologic studies have shown
clearly that malignancies are caused by exposures to
1,3-butadiene at levels equal to and below the current
federal occupational exposure standard of 1000 ppm
(2-4). NIOSH has urged already that the current stan-
dard be re-examined and has noted that while "the
excess risk of cancer to workers exposed to specific
airborne concentrations of 1,3-butadiene has not yet
beendetermined, . . . theprobabilityofdeveloping can-
cer could be decreased by reducing exposure" (23).
I caution strongly against further delaying the regu-
latory process while we await furtherepidemiologicand
toxicologic data on 1,3-butadiene (25). Sophisticated
research intoalternatemetabolic pathways (26) andinto
the possible role ofviruses (27) in the carcinogenicity of
1,3-butadiene is important. Such research should not,
however, be used as a basis for delaying reduction in
exposure standards either in this country or abroad.
Sufficient evidence exists today tojustify stringent re-
duction in exposure standards for 1,3-butadiene on the
grounds of prudent prevention.
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